Przewidywanie ciężkości COVID-19
Przewidywanie ciężkości COVID-19 za pomocą swoistego przeciwciała nukleokapsydowego i wskaźnika czynnika ryzyka choroby
Efficient strategies for predicting COVID-19 illness trajectories are urgently wanted. Right here, enzyme-linked immunosorbent assay (ELISA) and coronavirus antigen microarray (COVAM) evaluation mapped antibody epitopes within the plasma of COVID-19 sufferers (n = 86) experiencing a variety of illness states. The experiments recognized antibodies to a 21-residue epitope from nucleocapsid (termed Ep9) related to extreme illness, together with admission to the intensive care unit (ICU), requirement for ventilators, or demise.
Importantly, anti-Ep9 antibodies will be detected inside 6 days post-symptom onset and generally inside 1 day. Moreover, anti-Ep9 antibodies correlate with varied comorbidities and hallmarks of immune hyperactivity. We introduce a simple-to-calculate, illness threat issue rating to quantitate every affected person’s comorbidities and age. For sufferers with anti-Ep9 antibodies, scores above 3.Zero predict extra extreme illness outcomes with a 13.42 chance ratio (96.7% specificity).
The outcomes lay the groundwork for a brand new sort of COVID-19 prognostic to permit early identification and triage of high-risk sufferers. Such info might information more practical therapeutic intervention.IMPORTANCE The COVID-19 pandemic has resulted in over two million deaths worldwide. Regardless of efforts to struggle the virus, the illness continues to overwhelm hospitals with severely unwell sufferers.
Prognosis of COVID-19 is instantly completed by a mess of dependable testing platforms; nonetheless, prognostic prediction stays elusive. To this finish, we recognized a brief epitope from the SARS-CoV-2 nucleocapsid protein and likewise a illness threat issue rating primarily based upon comorbidities and age. The presence of antibodies particularly binding to this epitope plus a rating cutoff can predict extreme COVID-19 outcomes with 96.7% specificity.
Anti-IGF-IR antibody |
|||
| STJ93647 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: IGF-IR is a protein encoded by the IGF1R gene which is approximately 154,7 kDa. IGF-IR is localised to the cell membrane. It is involved in apoptotic pathways, the GPCR pathway and ERK signalling. It is a receptor tyrosine kinase which mediates actions of insulin-like growth factor 1. The activated protein is involved in cell growth and survival control and is also crucial for tumour transformation and survival of malignant cells. It is formed from two subunits, each of which is comprised of an extracellular alpha-subunit and a transmembrane beta-subunit with intracellular tyrosine kinase activity. IGF-IR is expressed in the nervous system, skin, pancreas, lung and muscle. Mutations in the IGF1R gene may result in insulin-like growth factor 1 resistance. STJ93647 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of IGF-IR protein. |
|||
Anti-IGF-IR antibody |
|||
| STJ93648 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to IGF-IR. |
|||
Anti-IGF-I antibody |
|||
| STJ93653 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to IGF-I. |
|||
Anti-IGF-IIR antibody |
|||
| STJ93654 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to IGF-IIR. |
|||
Anti-IGF-IIR antibody |
|||
| STJ93655 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to IGF-IIR. |
|||
Anti-IGF-IR antibody |
|||
| STJ93656 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to IGF-IR. |
|||
Anti-IGF-IR antibody |
|||
| STJ93657 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to IGF-IR. |
|||
Anti-IGF-IIR antibody |
|||
| STJ96634 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to IGF-IIR. |
|||
Anti-IGF-IR antibody |
|||
| STJ98158 | St John's Laboratory | 100 µl | EUR 234 |
|
Description: Mouse monoclonal to IGF-IR. |
|||
Anti-IGF-IR antibody |
|||
| STJ98159 | St John's Laboratory | 100 µl | EUR 234 |
|
Description: Mouse monoclonal to IGF-IR. |
|||
Polyclonal Goat anti-GST α-form |
|||
| GST-ANTI-1 | Detroit R&D | 50 uL | EUR 280 |
Polyclonal Goat anti-GST μ-form |
|||
| GST-ANTI-2 | Detroit R&D | 50 uL | EUR 280 |
Polyclonal Goat anti-GST p-form |
|||
| GST-ANTI-3 | Detroit R&D | 50 uL | EUR 280 |
anti-IGF-1R (Ab-1280) |
|||
| LF-PA20229 | Abfrontier | 100 ul | EUR 334 |
|
Description: Rabbit polyclonal to IGF-1R |
|||
anti-IGF-1R (Ab-1346) |
|||
| LF-PA20230 | Abfrontier | 100 ul | EUR 334 |
|
Description: Rabbit polyclonal to IGF-1R |
|||
anti-IGF-1R (Ab-1161) |
|||
| LF-PA20231 | Abfrontier | 100 ul | EUR 334 |
|
Description: Rabbit polyclonal to IGF-1R |
|||
anti-IGF-1R (Phospho-Tyr1161) |
|||
| LF-PA20233 | Abfrontier | 100 ul | EUR 354 |
|
Description: Rabbit polyclonal to IGF-1R (Phospho-Tyr1161) |
|||
Anti-Rat IGF-1 Antibody |
|||
| 5121-100 | Biovision | EUR 316 | |
Anti-Rat IGF-1 Antibody |
|||
| 5121-30T | Biovision | EUR 146 | |
Human Salivary IGF(salivary IGF) ELISA Kit |
|||
| QY-E05383 | Qayee Biotechnology | 96T | EUR 361 |
Anti-IGF-1R (Teprotumumab), Human IgG1 Antibody |
|||
| A2160-100 | Biovision | 100 µg | EUR 510 |
IGF-1, Human |
|||
| HY-P7018 | MedChemExpress | 10ug | EUR 108 |
IGF-2, Human |
|||
| HY-P7019 | MedChemExpress | 100ug | EUR 360 |
IGF-BP3, Human |
|||
| HY-P7020 | MedChemExpress | 10ug | EUR 234 |
IGF-BP5, Human |
|||
| HY-P7021 | MedChemExpress | 50ug | EUR 601 |
IGF-1, human |
|||
| RC216-12 | Bio Basic | 1mg | EUR 376.25 |
IGF-BP3, human |
|||
| RC216-12B3 | Bio Basic | 5ug | EUR 104.38 |
Anti-IGF-1R (Ab-1161) Antibody |
|||
| A00070-1 | BosterBio | 100ul | EUR 397 |
|
Description: Rabbit Polyclonal IGF-1R (Ab-1161) Antibody. Validated in IF, IHC, WB and tested in Human, Mouse, Rat. |
|||
Anti-Phospho-IGF-IIR (S2409) antibody |
|||
| STJ90923 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to Phospho-IGF-IIR (S2409). |
|||
Anti-Phospho-IGF-IR (Y1346) antibody |
|||
| STJ91187 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1346). |
|||
Anti-Phospho-IGF-IR (Y1161) antibody |
|||
| STJ90298 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1161). |
|||
Anti-Phospho-IGF-IR (Y1161) antibody |
|||
| STJ91026 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1161). |
|||
Polyclonal Anti-Rat IGF-1 Antibody |
|||
| APR00269G | Leading Biology | 0.1mg | EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Anti-Rat IGF-1 . This antibody is tested and proven to work in the following applications: |
|||
anti-IGF-1R (Ab-1165/1166) |
|||
| LF-PA20232 | Abfrontier | 100 ul | EUR 334 |
|
Description: Rabbit polyclonal to IGF-1R |
|||
anti-IGF-1R (Phospho-Tyr1165/Tyr1166) |
|||
| LF-PA20234 | Abfrontier | 100 ul | EUR 354 |
|
Description: Rabbit polyclonal to IGF-1R (Phospho-Tyr1165/Tyr1166) |
|||
IGF-II |
|||
| PR15045CF | Neuromics | 50 ug | EUR 278 |
Biotinyl Human IGF-I |
|||
| AQU010 | GroPep | 10 µg | EUR 253 |
Biotinyl Human IGF-I |
|||
| AQU050 | GroPep | 50 µg | EUR 346 |
Biotinyl Human IGF-I |
|||
| AQU100 | GroPep | 100 µg | EUR 531 |
Biotinyl Human IGF-I |
|||
| AQU500 | GroPep | 500 µg | EUR 1088 |
Human [Arg6] IGF-II |
|||
| GU020 | GroPep | 20 µg | EUR 253 |
Human [Ala31] IGF-I |
|||
| AIU100 | GroPep | 100 µg | EUR 346 |
Human [Ala31] IGF-I |
|||
| AIU020 | GroPep | 20 µg | EUR 253 |
Human IGF-I Protein |
|||
| abx060791-100ug | Abbexa | 100 ug | EUR 467 |
Human [Leu60] IGF-I |
|||
| ABU020 | GroPep | 20 µg | EUR 253 |
Human [Leu60] IGF-I |
|||
| ABU100 | GroPep | 100 µg | EUR 346 |
Human [Leu27]IGF-II |
|||
| TU100 | GroPep | 100 µg | EUR 346 |
Human [Leu24] IGF-I |
|||
| ZU020 | GroPep | 20 µg | EUR 253 |
Human [Leu24] IGF-I |
|||
| ZU100 | GroPep | 100 µg | EUR 346 |
IGF-1, human recombinant |
|||
| P1016-.02 | ApexBio | 20 µg | EUR 258 |
|
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue |
|||
IGF-II, human recombinant |
|||
| P1017-.01 | ApexBio | 10 µg | EUR 161 |
|
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family. |
|||
IGF-II, human recombinant |
|||
| P1017-.05 | ApexBio | 50 µg | EUR 313 |
|
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family. |
|||
IGF-II, human recombinant |
|||
| P1017-1 | ApexBio | 1 mg | EUR 1998 |
|
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family. |
|||
Human IGF-1 LR3 |
|||
| SP-89927-100 | Alpha Diagnostics | 100 ug | EUR 225 |
rec IGF-I (human) |
|||
| H-5555.0050 | Bachem | 50.0µg | EUR 242 |
|
Description: CAS# [67763-96-6] |
|||
rec IGF-I (human) |
|||
| H-5555.0100 | Bachem | 100.0µg | EUR 381 |
|
Description: CAS# [67763-96-6] |
|||
rec IGF-I (human) |
|||
| H-5555.0500 | Bachem | 0.5mg | EUR 1434 |
|
Description: CAS# [67763-96-6] |
|||
IGF-1, human recombinant |
|||
| P1016-.1 | ApexBio | 100 µg | EUR 763 |
|
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue |
|||
IGF-I, human recombinant |
|||
| 4119-100 | Biovision | EUR 175 | |
IGF-I, human recombinant |
|||
| 4119-1000 | Biovision | EUR 343 | |
IGF-I, human recombinant |
|||
| 4119-10MG | Biovision | EUR 1529 | |
IGF-I, human recombinant |
|||
| 4119-1G | Biovision | EUR 41157 | |
IGF-I, human recombinant |
|||
| 4119-20MG | Biovision | EUR 2328 | |
IGF-I, human recombinant |
|||
| 4119-5000 | Biovision | EUR 958 | |
IGF-I, human recombinant |
|||
| 4119-50MG | Biovision | EUR 4220 | |
IGF-II, human recombinant |
|||
| 4122-10 | Biovision | EUR 137 | |
IGF-II, human recombinant |
|||
| 4122-1000 | Biovision | EUR 1572 | |
IGF-II, human recombinant |
|||
| 4122-50 | Biovision | EUR 256 | |
IGF-BP1, human recombinant |
|||
| 4717-100 | Biovision | EUR 620 | |
IGF-BP1, human recombinant |
|||
| 4717-1000 | Biovision | EUR 3149 | |
IGF-BP1, human recombinant |
|||
| 4717-25 | Biovision | EUR 256 | |
IGF-BP3, human recombinant |
|||
| 4720-100 | Biovision | EUR 620 | |
IGF-BP3, human recombinant |
|||
| 4720-1000 | Biovision | EUR 3149 | |
IGF-BP3, human recombinant |
|||
| 4720-25 | Biovision | EUR 256 | |
IGF-BP5, human recombinant |
|||
| 4723-100 | Biovision | EUR 620 | |
IGF-BP5, human recombinant |
|||
| 4723-1000 | Biovision | EUR 3149 | |
IGF-BP5, human recombinant |
|||
| 4723-25 | Biovision | EUR 256 | |
IGF-BP2, human recombinant |
|||
| 7165-10 | Biovision | EUR 251 | |
IGF-BP2, human recombinant |
|||
| 7165-50 | Biovision | EUR 936 | |
IGF-BP7, human recombinant |
|||
| 7167-10 | Biovision | EUR 207 | |
IGF-BP7, human recombinant |
|||
| 7167-50 | Biovision | EUR 675 | |
IGF-BP6, human recombinant |
|||
| 7350-20 | Biovision | EUR 370 | |
IGF-2/ Rat IGF- 2 ELISA Kit |
|||
| ELA-E0051r | Lifescience Market | 96 Tests | EUR 886 |
Anti-IGF1/Igf I Rabbit Monoclonal Antibody |
|||
| M00148 | BosterBio | 100ug/vial | EUR 397 |
|
Description: Rabbit Monoclonal IGF1/Igf I Antibody. Validated in WB and tested in Human. |
|||
Anti-IGF2/Igf Ii Rabbit Monoclonal Antibody |
|||
| M00335 | BosterBio | 100ug/vial | EUR 397 |
|
Description: Rabbit Monoclonal IGF2/Igf Ii Antibody. Validated in IF, WB and tested in Human. |
|||
Anti-Phospho-IGF-IR (Y1165/Y1166) antibody |
|||
| STJ90299 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1165/Y1166). |
|||
Mouse Anti-Human IGF-1R monoclonal antibody, clone JID716 |
|||
| CABT-L2807-100uL500uL | Creative Diagnostics | 100 uL, 500 uL | EUR 502 |
Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-100ug |
|||
| QP8601-ec-100ug | EnQuireBio | 100ug | EUR 408 |
Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-10ug |
|||
| QP8601-ec-10ug | EnQuireBio | 10ug | EUR 200 |
Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-1mg |
|||
| QP8601-ec-1mg | EnQuireBio | 1mg | EUR 1632 |
Związek między poziomami alarmin w surowicy a wskaźnikami specyficznymi dla choroby u pacjentów z zapaleniem naczyń związanym z cytoplazmatycznymi przeciwciałami przeciw neutrofilom
Background/purpose: We evaluated the connection between serum alarmin ranges and disease-specific indices in sufferers with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Sufferers and strategies: Sera and information from 79 sufferers had been utilized. For AAV-specific indices, Birmingham vasculitis exercise rating (BVAS), five-factor rating (FFS), and vasculitis harm index (VDI) had been collected and serum ranges of 4 alarmins (hepatoma-derived progress issue, excessive mobility group field protein 1, S100A9, and S100A12) had been measured utilizing enzyme-linked immunosorbent assay. Associations between alarmin ranges, AAV-specific indices, and inflammatory laboratory markers had been assessed.
Outcomes: S100A9 ranges had been considerably correlated with C-reactive protein ranges (r=0.316, p=0.005) and S100A12 ranges correlated with VDI (r=0.232, p=0.040), which was constant in a subgroup of sufferers with myeloperoxidase (perinuclear)-ANCA positivity. No different associations had been discovered between alarmin ranges and BVAS, FFS, and VDI.
Conclusion: The serum S100A12 degree was related to organ harm in AAV, particularly in myeloperoxidase (perinuclear)-ANCA-positive sufferers.
Zapalenie skórno-mięśniowe z dodatnim przeciwciałem anty-MDA5 z szybko postępującą śródmiąższową chorobą płuc: opis dwóch przypadków
Melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) shows distinctive cutaneous and pathologic options. We describe two circumstances of myositis-associated quickly progressive interstitial lung illness (RP-ILD).
The sufferers had been two girls from Kerala, India. Each sufferers had anti-MDA5 antibody-positive myositis. Each sufferers offered with RP-ILD with none scientific options of myositis and succumbed to their sickness regardless of aggressive medical therapy. Anti-MDA5-antibody-positive DM is characterised by amyopathic illness with quickly progressive and deadly ILD.
Charakterystyka przeciwciał monoklonalnych przeciw tężcowi jako pierwszy krok w kierunku opracowania testu immunologicznego na siłę szczepionki in vitro
Batch launch testing for human and veterinary tetanus vaccines nonetheless depends closely on strategies that contain animals, notably for efficiency testing. The amount and high quality of tetanus antigen current in these merchandise is of utmost significance for product security and scientific impact. Immunochemical strategies that measure consistency of antigen content material and high quality, doubtlessly as an indicator of efficiency, may very well be a better option and negate the necessity for an in vivo efficiency check. These immunochemical strategies require at the least one nicely characterised monoclonal antibody (mAb) that’s particular for the goal antigen. On this paper we report the outcomes of the excellent characterisation of a panel of mAbs towards tetanus with a view to pick antibodies that can be utilized for improvement of an in vitro efficiency immunoassay.
We’ve assessed binding of the antibodies to native antigen (toxin), detoxified antigen (toxoid), adsorbed antigen and heat-altered antigen. Antibody perform was decided utilizing an in-house cell-based neutralisation assay to assist prior in vivo efficiency information that was obtainable for some, however not all, of the antibodies. As well as, antibody affinity was measured, and epitope competitors evaluation was carried out to establish pairs of antibodies that may very well be deployed in a sandwich immunoassay format. Not all characterisation assessments offered proof of “superiority” of 1 mAb over one other, however collectively the outcomes from all characterisation research allowed for choice of an antibody pair to be taken ahead to assay improvement.
Opis przypadku: autoimmunologiczne zapalenie mózgu związane z przeciwciałami dekarboksylazy kwasu przeciwglutaminowego: seria przypadków pediatrycznych
Background: Antibodies towards glutamic acid decarboxylase (GAD) are related to varied neurologic circumstances described in sufferers, together with stiff particular person syndrome, cerebellar ataxia, refractory epilepsy, and limbic and extralimbic encephalitis. There have been some case stories and investigations relating to anti-GAD65 antibody-associated encephalitis in grownup populations, however pediatric circumstances are uncommon. We retrospectively analyzed the scientific information of three anti-GAD65 antibody-positive sufferers to discover the range and scientific options of anti-GAD65 antibody-associated pediatric autoimmune encephalitis.
Strategies: The scientific information of a sequence of three sufferers optimistic for anti-GAD65 antibody had been retrospectively analyzed. GAD65 antibodies had been decided in serum and CSF utilizing a cell-based assay.
Outcomes: All three sufferers had been feminine, and the onset ages had been four years and 9 months, 6 years, and 16 years previous. Their scientific phenotypes included autoimmune limbic encephalitis, extralimbic encephalitis, and encephalitis combining limbic and extralimbic encephalitis. The scientific signs included seizures, reminiscence deficits, drowsiness, dysautonomia, and headache. All sufferers had irregular carinal MRI and EEG. All sufferers obtained immunotherapy and had transiently good responsiveness, however one affected person then skilled relapse. In follow-up, one affected person with extralimbic encephalitis recovered utterly, whereas two sufferers with limbic involvement had poor outcomes with refractory focal epilepsy.
Conclusion: Along with limbic encephalitis, extralimbic encephalitis can also be an necessary phenotype in sufferers who’re optimistic for anti-GAD65 antibodies. Early analysis and immunotherapy can enhance the signs. Nevertheless, sufferers with limbic encephalitis typically have refractory epilepsy within the continual section and have a poor long-term final result.
NAP-2/CXCL7, Rat |
|||
| HY-P7269 | MedChemExpress | 50ug | EUR 533 |
NAP-2/CXCL7, Human |
|||
| HY-P7268 | MedChemExpress | 50ug | EUR 533 |
NAP-2, CXCL7, human |
|||
| RC312-18 | Bio Basic | 2ug | EUR 104.38 |
NAP-2, CXCL7, rat |
|||
| RC352-18 | Bio Basic | 2ug | EUR 104.38 |
CXCL7 ELISA KIT|Human |
|||
| EF001450 | Lifescience Market | 96 Tests | EUR 689 |
Human CXCL7 ELISA Kit |
|||
| LF-EK50893 | Abfrontier | 1×96T | EUR 648 |
Mouse beta Thromboglobulin (CXCL7/bTG) CLIA Kit |
|||
| 20-abx491403 | Abbexa |
|
|
Human CXCL7 PicoKine ELISA Kit |
|||
| EK0729 | BosterBio | 96 wells | EUR 425 |
|
Description: For quantitative detection of human CXCL7 in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA). |
|||
Human CXCL7 AssayMax ELISA Kit |
|||
| EC2270-1 | AssayPro | 96 Well Plate | EUR 477 |
Human CXCL7 Antibody (Biotin Conjugate) |
|||
| 32852-05121 | AssayPro | 150 ug | EUR 369 |
ELISA kit for Human CXCL7 |
|||
| EK5304 | SAB | 96 tests | EUR 553 |
|
Description: Enzyme-linked immunosorbent assay kit for quantification of Human CXCL7 in samples from serum, plasma, tissue homogenates and other biological fluids. |
|||
ThymusChemokine‑1/CXCL7 (CHO-expressed), Rat |
|||
| HY-P7301 | MedChemExpress | 10ug | EUR 291 |
Rat PPBP/CXCL7 PicoKine ELISA Kit |
|||
| EK0731 | BosterBio | 96 wells | EUR 425 |
|
Description: For Quantitative Detection of rat CXCL7 in cell culture supernates, serum and plasma (heparin, EDTA). |
|||
NAP-2/CXCL7 (CHO-expressed), Human |
|||
| HY-P7267 | MedChemExpress | 50ug | EUR 497 |
Neutrophil Activating Protein-2 (CXCL7) Antibody |
|||
| 20-abx137035 | Abbexa |
|
|
Neutrophil Activating Protein-2 (CXCL7) Protein |
|||
| 20-abx261559 | Abbexa |
|
|
Neutrophil Activating Protein-2 (CXCL7) Protein |
|||
| 20-abx261561 | Abbexa |
|
|
Human CXCL7 AssayLite Antibody (FITC Conjugate) |
|||
| 32852-05141 | AssayPro | 150 ug | EUR 428 |
Human CXCL7 AssayLite Antibody (RPE Conjugate) |
|||
| 32852-05151 | AssayPro | 150 ug | EUR 428 |
Human CXCL7 AssayLite Antibody (APC Conjugate) |
|||
| 32852-05161 | AssayPro | 150 ug | EUR 428 |
Human CXCL7 AssayLite Antibody (PerCP Conjugate) |
|||
| 32852-05171 | AssayPro | 150 ug | EUR 471 |
Recombinant Human CXCL7/NAP-2 Protein |
|||
| RP00829 | Abclonal | 10 μg | EUR 221 |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7) |
|||
| 7-02059 | CHI Scientific | 2µg | Ask for price |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7) |
|||
| 7-02060 | CHI Scientific | 10µg | Ask for price |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7) |
|||
| 7-02061 | CHI Scientific | 1mg | Ask for price |
Recombinant Rat Neutrophil Activating Protein-2 (CXCL7) |
|||
| 7-02065 | CHI Scientific | 2µg | Ask for price |
Recombinant Rat Neutrophil Activating Protein-2 (CXCL7) |
|||
| 7-02066 | CHI Scientific | 10µg | Ask for price |
Recombinant Rat Neutrophil Activating Protein-2 (CXCL7) |
|||
| 7-02067 | CHI Scientific | 1mg | Ask for price |
Human CXCL7(Platelet basic protein) ELISA Kit |
|||
| EH0007 | FN Test | 96T | EUR 567.6 |
|
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 9.375pg/ml |
|||
ELISA kit for Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) |
|||
| E-EL-M1269 | Elabscience Biotech | 1 plate of 96 wells | EUR 534 |
|
Description: A sandwich ELISA kit for quantitative measurement of Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant |
|||
Pig Platelet Basic Protein / CXCL7 (PPBP) ELISA Kit |
|||
| abx511493-96tests | Abbexa | 96 tests | EUR 911 |
Rat Platelet Basic Protein / CXCL7 (PPBP) ELISA Kit |
|||
| abx255841-96tests | Abbexa | 96 tests | EUR 668 |
Neutrophil Activating Protein-2 (CXCL7), 95 a.a. Protein |
|||
| 20-abx260678 | Abbexa |
|
|
Human Platelet Basic Protein / CXCL7 (PPBP) ELISA Kit |
|||
| abx252283-96tests | Abbexa | 96 tests | EUR 668 |
Recombinant (E.Coli) Human Neutrophil Activating Protein-2 (CXCL7) |
|||
| RP-1008 | Alpha Diagnostics | 10 ug | EUR 286 |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7), 95 a.a. |
|||
| 7-02062 | CHI Scientific | 2µg | Ask for price |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7), 95 a.a. |
|||
| 7-02063 | CHI Scientific | 10µg | Ask for price |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7), 95 a.a. |
|||
| 7-02064 | CHI Scientific | 1mg | Ask for price |
Human Thromboglobulin, Beta (bTG/PBP/CXCL7/NAP2) CLIA Kit |
|||
| abx197774-96tests | Abbexa | 96 tests | EUR 825 |
ELISA kit for Rat ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) |
|||
| E-EL-R1087 | Elabscience Biotech | 1 plate of 96 wells | EUR 534 |
|
Description: A sandwich ELISA kit for quantitative measurement of Rat ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant |
|||
Human CXCL7 EZ-Set™ ELISA Kit (DIY Antibody Pairs) |
|||
| EZ0729 | BosterBio | 5 plates/kit | EUR 268 |
|
Description: For the development of sandwich ELISA kit to measure human CXCL7 in cell culture supernates, cell lysates, tissue homogenates, serum and plasma (heparin, EDTA). |
|||
ELISA kit for Human ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) |
|||
| E-EL-H1007 | Elabscience Biotech | 1 plate of 96 wells | EUR 534 |
|
Description: A sandwich ELISA kit for quantitative measurement of Human ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Plasma |
|||
NAP-2 Neutrophil Activating Protein-2 Human Recombinant Protein (CXCL7) |
|||
| PROTP02775 | BosterBio | Regular: 10ug | EUR 317 |
|
Description: Neutrophil Activating Protein-2 Human Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 70 amino acids and having a molecular mass of 7609 Dalton. ;The NAP-2 is purified by proprietary chromatographic techniques. |
|||
NAP-2 Neutrophil Activating Protein-2 Rat Recombinant Protein (CXCL7) |
|||
| PROTQ99ME0 | BosterBio | Regular: 10ug | EUR 317 |
|
Description: NAP-2 Rat Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 62 amino acids and having a molecular mass of 6.8kDa.;The NAP 2 is purified by proprietary chromatographic techniques. |
|||
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-100ug |
|||
| QP8641-ec-100ug | EnQuireBio | 100ug | EUR 408 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-10ug |
|||
| QP8641-ec-10ug | EnQuireBio | 10ug | EUR 200 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-1mg |
|||
| QP8641-ec-1mg | EnQuireBio | 1mg | EUR 1632 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-200ug |
|||
| QP8641-ec-200ug | EnQuireBio | 200ug | EUR 634 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-500ug |
|||
| QP8641-ec-500ug | EnQuireBio | 500ug | EUR 1060 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-50ug |
|||
| QP8641-ec-50ug | EnQuireBio | 50ug | EUR 263 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-100ug |
|||
| QP10212-ec-100ug | EnQuireBio | 100ug | EUR 988 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-10ug |
|||
| QP10212-ec-10ug | EnQuireBio | 10ug | EUR 290 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-250ug |
|||
| QP10212-ec-250ug | EnQuireBio | 250ug | EUR 1731 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-2ug |
|||
| QP10212-ec-2ug | EnQuireBio | 2ug | EUR 154 |
Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-100ug |
|||
| QP10285-ec-100ug | EnQuireBio | 100ug | EUR 1178 |
Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-10ug |
|||
| QP10285-ec-10ug | EnQuireBio | 10ug | EUR 290 |
Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-250ug |
|||
| QP10285-ec-250ug | EnQuireBio | 250ug | EUR 2067 |
Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-2ug |
|||
| QP10285-ec-2ug | EnQuireBio | 2ug | EUR 154 |
Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2 |
|||
| C056-10ug | Novoprotein | 10ug | EUR 202 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2 |
|||
| C056-1mg | Novoprotein | 1mg | EUR 2283 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2 |
|||
| C056-500ug | Novoprotein | 500ug | EUR 1613 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2 |
|||
| C056-50ug | Novoprotein | 50ug | EUR 496 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
NAP-2-95 Neutrophil Activating Protein-2 (CXCL7) Human Recombinant Protein, 95 a.a. |
|||
| PROTP02775-1 | BosterBio | Regular: 10ug | EUR 317 |
|
Description: NAP 2 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 95 amino acids (35-128) and having a molecular mass of 10.3 kDa.;The NAP 2 is purified by proprietary chromatographic techniques. |
|||
Mouse Anti-FcεRIα |
|||
| MOFCeRIaAP(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaAP(V25) | ImmunoStep | 25 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaB(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaB(V25) | ImmunoStep | 25 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaCFB(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaCFB(V25) | ImmunoStep | 25 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaF(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaF(V25) | ImmunoStep | 25 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaF(V500) | ImmunoStep | 500 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaPE(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaPE(V25) | ImmunoStep | 25 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaPP(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaPP(V25) | ImmunoStep | 25 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaPP55(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaPP55(V25) | ImmunoStep | 25 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaPU(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-FcεRIα |
|||
| MOFCeRIaPU(V500) | ImmunoStep | 500 ug | EUR 50 |
Mouse Anti-IL2 |
|||
| MOIL2A(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-IL2 |
|||
| MOIL2A(V25) | ImmunoStep | 25 ug | EUR 50 |
Mouse Anti-IL2 |
|||
| MOIL2B(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-IL2 |
|||
| MOIL2B(V25) | ImmunoStep | 25 ug | EUR 50 |
Mouse Anti-IL2 |
|||
| MOIL2CFB(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-IL2 |
|||
| MOIL2CFB(V25) | ImmunoStep | 25 ug | EUR 50 |
Mouse Anti-IL2 |
|||
| MOIL2F(V100) | ImmunoStep | 100 ug | EUR 50 |
Mouse Anti-IL2 |
|||
| MOIL2F(V25) | ImmunoStep | 25 ug | EUR 50 |
Mouse Anti-IL2 |
|||
| MOIL2F(V500) | ImmunoStep | 500 ug | EUR 50 |
Mouse Anti-IL2 |
|||
| MOIL2PE(V100) | ImmunoStep | 100 ug | EUR 50 |
